Last updated on January 2019

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies


Brief description of study

This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies

Clinical Study Identifier: NCT03453619

Find a site near you

Start Over

Apellis Investigational Site

Wilmington, NC United States
  Connect »

Apellis Investigational Site

Alexandria, VA United States
  Connect »

Apellis Investigational Site

Stanford, CA United States
  Connect »

Apellis Investigational Site

Washington, WA United States
  Connect »

Apellis Investigational Site

Coral Gables, FL United States
  Connect »

Apellis Investigational Site

Takoma Park, MD United States
  Connect »

Apellis Investigational Site

Kansas City, MO United States
  Connect »

Apellis Investigational Site

Chesapeake, VA United States
  Connect »

Apellis Investigational Site

Wauwatosa, WI United States
  Connect »

Apellis Investigational Site

Louisville, KY United States
  Connect »

Apellis Investigational Site

Shreveport, LA United States
  Connect »

Apellis Investigational Site

Valhalla, NY United States
  Connect »

Apellis Investigational Site

Cincinnati, OH United States
  Connect »